Latest From Biotech Now

The Future of Biodefense: Will Public-Private Partnerships Continue?

commercial-jenn

Ten years ago, in the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies.  Individuals from both political parties – many who had experienced bioterror first hand – worked together to harness the power of innovative science and tackle this national security threat. The ten year initiative was Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

New Drug Disposal Law Doesn’t Make Sense

rxpills-btn

Product stewardship is a broad term applied across many industries, encompassing environmental, health, and safety concerns. Companies in each sector of the biotech industry (healthcare, agricultural, and industrial and environmental) have championed stewardship programs for many years – not just because it makes good business sense, but because they believe it is the right thing to do. Within the healthcare space, the impact of pharmaceuticals in the environment has become an issue of emerging debate. Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Are Politics Killing the U.S. Animal Biotech Industry?

salmon

A number of national newspapers ran an in-depth Associated Press article this week on the continuing saga of the AquAdvantage salmon and the challenge of its developer, Massachusetts-based AquaBounty Technologies, to stay afloat. The fish, genetically engineered to reach market weight in half the time of a conventional salmon, is a sustainable answer to the world’s demand for high-quality seafood protein, but its application for approval with the U.S. Food and Drug Administration (FDA) remains Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Housing Inventory Going Fast

Chicago

With roughly 80,000 bioscience jobs in more than 3,500 businesses across all bioscience sectors, it is no wonder the 2013 BIO International Convention is returning to Chicago, April 22- 25, 2013. With a large presence in all biotech sectors – agricultural feedstock and chemicals, drugs and pharma, medical devices and equipment, research, testing and medical laboratories and bioscience-related distribution, attendees will have the opportunity to meet with and visit premier R&D facilities, from national laboratories Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,